Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients - PubMed (original) (raw)

. 2010 Sep;33(9):1997-2003.

doi: 10.2337/dc10-0476. Epub 2010 Jun 14.

Matteo Monami, Daniela Balzi, Barbara Cresci, Laura Pala, Cecilia Melani, Caterina Lamanna, Ilaria Bracali, Michela Bigiarini, Alessandro Barchielli, Niccolo Marchionni, Carlo Maria Rotella

Affiliations

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients

Edoardo Mannucci et al. Diabetes Care. 2010 Sep.

Abstract

Objective: Recent epidemiological studies suggested that some insulin analogues could be associated with increased risk of cancer. The present study is aimed at assessing the long-term association of different insulin analogues with cancer incidence.

Research design and methods: A nested case-control study dataset was generated from the cohort study dataset (n = 1,340 insulin-treated diabetic outpatients) by sampling control subjects from the risk sets. For each case subject, the control subjects (up to five) were chosen randomly from those members of the cohort who are at risk for the same follow-up time of the case subject. Five-year age classes, sex, and BMI classes (<18.5, 18.5-24.9, 25-29.9, and >or=30 kg/m(2)) were considered as additional categorical matching variables.

Results: During a median follow-up of 75.9 months (interquartile range 27.4-133.7), 112 case subjects of incident cancer were compared with 370 matched control subjects. A significantly higher mean daily dose of glargine was observed in case subjects than in control subjects (0.24 IU/kg/day [0.10-0.39] versus 0.16 IU/kg/day [0.12-0.24], P = 0.036). Incident cancer was associated with a dose of glargine >or=0.3 IU/kg/day even after adjusting for Charlson comorbidity score, other types of insulin administration, and metformin exposure (odds ratio 5.43 [95% CI 2.18-13.53], P < 0.001). No association between incident cancer and insulin doses was found for human insulin or other analogues.

Conclusions: The possibility of association between cancer and higher glargine doses suggests that dosages should always be considered when assessing the possible association of insulin and its analogues with cancer.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Risk of cancer associated with doses of each insulin type ≥0.3 IU/kg/day, adjusted for comorbidity, exposure to metformin, and doses of other types of insulin. ○, all case subjects; ●, after exclusion of case subjects with cancer occurring within the first 12 months of observation and of their matched control subjects.

Similar articles

Cited by

References

    1. Monami M, Marchionni N, Mannucci E: Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184–189 - PubMed
    1. The SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Res Network Epidemiology Group. Diabetologia 2009. [Epub ahead of print] - PMC - PubMed
    1. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732–1744 - PMC - PubMed
    1. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G: Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 2009;52:1745–1754 - PubMed
    1. Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766–1777 - PubMed

MeSH terms

Substances

LinkOut - more resources